---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015401"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T05:15:28.117074+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharma announces Ketamir-2 publication, Phase 1 progress, SKNY acquisition update

## Summary
- Ketamir-2 accepted for publication in Frontiers in Pharmacology; highlights selective NMDA antagonism, no hyperlocomotion, improved oral bioavailability.
- Phase 1 trial advancing as planned with dose escalation ongoing; no reported safety concerns.
- Phase 2a trial in neuropathic pain expected to initiate by year-end 2025, pending regulatory clearance.
- Acquisition of SKNY Pharmaceuticals (including SKNY-1 for obesity/smoking cessation) progressing; SEC filings submitted.

## SEC filing metadata
- accession: 0001641172-25-015401
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225015401/0001641172-25-015401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225015401/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015401
- JSON: https://secwatch.observer/filing/0001641172-25-015401.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.